lucanthone
Small moleculeexperimental
Lucanthone is a thioxanthenone DNA intercalator. It inhibits topoisomerases and the dual function base excision repair enzyme apurinic endonuclease 1. Lucanthone has been devised for the treatment of schistosomiasis. It is also an antitumor agent. Lucanthone was being developed by Spectrum Pharmaceuticals for the treatment of malignant brain tumours. — NCATS
Clinical trial activity
2 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01587144)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Vacuolar aminopeptidase 1INHIBITOR
inhibitor - APE1
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12- Mol. weight
- 340.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL279014 ↗
- NCATSFC6D57000M ↗
- ChEMBLCHEMBL2007389 ↗
Also known as
- 1-((2-(diethylamino)ethyl)amino)-4-methylthioxanthen-9-one
- 1-((2-(diethylamino)ethyl)amino)-4-methylthioxanthen-9-one
- 1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one
- 1-{[2-(diethylamino)ethyl]amino}-4-methylthioxanthen-9-one
- 1-diethylaminoethylethylamino-4-methyl-thioxanthenone
- 1-diethylaminoethylethylamino-4-methyl-thioxanthenone
- 79 t61
- 79 t61
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone
- lucanthone hcl
- lucanthone hcl
- lucanthone hcl
- lucanthone hydrochloride
- lucanthone hydrochloride
- lucanthone hydrochloride
- lucanthonum
- lucanthonum
- lucantona
- lucantona
- miracil
- miracil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02014545 | Phase 2 | Jan 1, 2016 | Spectrum Pharmaceuticals, Wake Forest University |
| NCT01587144 | Phase 2 | Mar 1, 2012 | Bhagwan Mahaveer Jain Hospital, Chittaranjan National Cancer Institute, Dent Neurologic Institute, Gujarat Cancer & Research Institute, Jaslok Hospital and Research Centre, Mumbai, India, Spectrum Pharmaceuticals, University of California, Irvine, University of California, San Diego, University of Rochester |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals | For profit | 2 | 1 | 1 | 2012 |
| Bhagwan Mahaveer Jain Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Chittaranjan National Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Dent Neurologic Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Gujarat Cancer & Research Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Jaslok Hospital and Research Centre, Mumbai, India | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Wake Forest University | Academic/Hospital | 1 | 1 | 1 | 2016 |
10 organizations
Page 1 / 1